New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:09 EDTBIIB, SGMOBiogen and Sangamo collaborate for hemoglobinopathy treatment development
Biogen (BIIB) and Sangamo (SGMO) announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. Sangamo is responsible for all research and development activities, and both companies will perform activities to enable submission of an Investigational New Drug Application for SCD. Biogen will provide Sangamo with an upfront payment of $20M and will reimburse Sangamo for its internal and external research and development program-related costs. Sangamo may also receive additional payments of approximately $300M based on the achievement of certain milestones, as well as double digit royalties on product sales.
News For BIIB;SGMO From The Last 14 Days
Check below for free stories on BIIB;SGMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:26 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
September 23, 2014
10:02 EDTSGMOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:03 EDTSGMOSangamo initiated with a Buy at Jefferies
Subscribe for More Information
September 22, 2014
07:21 EDTBIIBEBD Group to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use